Who are Anti-HBV antiviral prophylaxis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Docosanol 10%, ACYC vehicle, Standard of Care Antiviral medications, Antiviral Agents.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-hbv-antiviral-prophylaxis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti-HBV antiviral prophylaxis — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-HBV antiviral prophylaxis (Anti-HBV antiviral prophylaxis) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral agent. Area: Infectious Disease / Virology.

phase 3 Antiviral agent Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-HBV antiviral prophylaxis (Anti-HBV antiviral prophylaxis) — Institut de Recherche pour le Developpement. Anti-HBV antiviral prophylaxis prevents hepatitis B virus infection or reactivation by inhibiting viral replication through antiviral mechanisms.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-HBV antiviral prophylaxis TARGET	Anti-HBV antiviral prophylaxis	Institut de Recherche pour le Developpement	phase 3	Antiviral agent
Docosanol 10%	Docosanol 10%	Hadassah Medical Organization	marketed	Antiviral agent	Viral membrane fusion machinery
ACYC vehicle	ACYC vehicle	Bausch Health Americas, Inc.	phase 3	Antiviral agent (topical formulation)	Viral DNA polymerase (via acyclovir active ingredient)
Standard of Care Antiviral medications	Standard of Care Antiviral medications	New York Medical College	phase 3	Antiviral agent (class varies by specific drug)
Antiviral Agents	Antiviral Agents	Pregistry	phase 3	Antiviral agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral agent class)

Hadassah Medical Organization · 1 drug in this class
Institut de Recherche pour le Developpement · 1 drug in this class
Pregistry · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-HBV antiviral prophylaxis — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-hbv-antiviral-prophylaxis. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab